ライフサイエンスコーパス: platelet factor 4

1 thrombocytopenia and antibodies against PF4 (platelet factor 4).

2 ene for another platelet-specific chemokine, platelet factor 4.

3 such as transforming growth factor beta1 or platelet factor 4.

4 , with more than 80% of them also containing platelet factor 4.

5 llebrand factor (VWF), thrombospondin-1, and platelet factor 4.

6 :Ag) and propeptide (VWFpp), P-selectin, and platelet factor 4.

7 wth factor-2 binding but a weak affinity for platelet factor-4.

8 Platelet factor 4, a metric of platelet activation, was

9 subjects with severe asthma, whereas plasma platelet factor 4, a second platelet activation marker,

10 compared to other heparin-binding proteins (platelet factor 4 and antithrombin III), and diminished

11 rollary of these concepts is that disrupting platelet factor 4 and beta(2)GPI conformation (or ultral

12 and analyzed for sCD40L, interleukin-6, and platelet factor 4 and beta-thromboglobulin (markers of p

13 In contrast, platelet factor 4 and beta-thromboglobulin do not appear

14 HTTLPR l/l genotype had significantly higher platelet factor 4 and beta-thromboglobulin levels.

15 re more cognitively impaired, and had higher platelet factor 4 and beta-thromboglobulin levels; cardi

16 gin as other markers of platelet activation, platelet factor 4 and beta-thromboglobulin, were not inc

17 of CPB and was similar to that observed for platelet factor 4 and beta-thromboglobulin.

18 th antibodies to complexes that form between platelet factor 4 and glycosaminoglycan (GAG) side chain

19 ibodies to a multivalent antigen composed of platelet factor 4 and heparin.

20 tibodies against multimolecular complexes of platelet factor 4 and heparin.

21 Platelet-transported inflammatory mediators platelet factor 4 and serotonin accumulated in the graft

22 ibodies over 1 week sustained high levels of platelet factor 4 and serotonin.

23 ts demonstrated that P-selectin, fibrinogen, platelet factor 4 and vascular endothelial growth factor

24 correlated with plasma levels of P-selectin, platelet factor 4, and platelet basic protein in the pop

25 ble factors serotonin (5-hydroxytryptamine), platelet factor 4, and platelet-activating factor, which

26 analyzed with ELISA for soluble P-selectin, platelet factor 4, and thrombospondin-1.

27 binding proteins, such as protamine sulfate, platelet factor-4, and beta-thromboglobulin.

28 us thrombosis with thrombocytopenia and anti-platelet factor 4 (anti-PF4) antibodies in individuals f

29 disorder associated with development of anti-platelet factor 4 (anti-PF4)/heparin autoantibodies.

30 Kanack and colleagues analyze anti-platelet factor 4 antibodies from 5 patients with vaccin

31 he case of VITT, also by platelet-activating platelet factor 4 antibodies reminiscent of heparin-indu

32 lts (including the results of tests for anti-platelet factor 4 antibodies where available), and radio

33 in association with platelet-activating anti-platelet factor 4 antibodies.

34 thromboembolism, results of heparin-induced platelet factor 4 antibody tests, and outcomes.

35 e Western blotting of factor V, prothrombin, platelet factor 4, antithrombin III, and fibrinogen.

36 Autoantibodies to platelet factor-4 are associated with catastrophic throm

37 kines, PBP (platelet basic protein) and PF4 (platelet factor 4), are within 5.3 kilobases (kb) of eac

38 Platelet factor 4, beta-thromboglobulin (betaTG), platel

39 The alpha-granule proteins platelet factor 4, beta-thromboglobulin, and platelet-de

40 role for platelets and their products (e.g., platelet factor 4, beta-thromboglobulin, RANTES, thrombo

41 parin-derived "Enoxaparin" showed comparable platelet factor-4 binding affinity, suggesting that it s

42 We now show that platelet factor 4 binds to monocytes and forms antigenic

43 ogical criteria and by positive reaction for platelet factor-4 by Western blotting.

44 n has improved in recent years, with heparin-platelet factor 4 complex as the culprit antigen in most

45 shown that antibodies reactive with heparin-platelet factor 4 complexes lead to FcgammaRIIA-mediated

46 se assay (SRA) and for antibodies to heparin/platelet factor 4 complexes with an ELISA.

47 7082, or TPCA-1) or by genetic manipulation (platelet factor 4 Cre:IKK-beta(flox/flox)), blocked SNAP

48 The Platelet factor 4-Cre recombinase (Pf4-Cre) transgenic m

49 Platelet factor 4-Cre-mediated deletion of Slp-76 is suf

50 t survival and decreased plasma thromboxane, platelet factor 4 (CXCL4), and IFN-gamma.

51 tion factor (M-CSF), and chemokines, such as platelet factor 4 (CXCL4).

52 lease of pro-inflammatory chemokines such as platelet factor 4 (CXCL4/PF4), are associated with perio

53 t is for GAG, its binding is not competed by platelet factor 4/CXCL4, and it is present on cells that

54 Platelet factor 4 did not correlate.

55 -induced platelet activation (HIPA) test and platelet factor 4-enhanced HIPA (PIPA).

56 While the biological basis of platelet factor 4 expression has been pursued by others,

57 lasmic maturation (ie, glycoprotein GPIb and platelet factor 4 expression) and reduced the ability of

58 -reactive protein, beta-thromboglobulin, and platelet factor 4 (Hedges' gs = -0.23 to 0.02, ps >= 0.0

59 tibodies show several similarities with anti-platelet factor 4-heparin antibodies and are a potential

60 ted with a high incidence of IgG Abs against platelet factor 4/heparin (PF4/H) complexes by day 6 aft

61 a 4Ts score, rapid particle gel immunoassay (platelet factor 4/heparin [PF4/H]-PaGIA), and serotonin-

62 An immune-mediated response associated with platelet factor 4/heparin antibodies has been proposed a

63 Heparin-induced thrombocytopenia with platelet factor 4/heparin antibodies was diagnosed in a

64 An ELISA for anti-platelet factor 4/heparin antibodies was performed using

65 Platelet factor 4/heparin antibodies were quantified usi

66 on, and heparin-induced thrombocytopenia and platelet factor 4/heparin antibodies were rare.

67 ruary 2016 were analyzed for the presence of platelet factor 4/heparin antibodies.

68 rombocytopenia, and none (95% CI, 0%-4%) had platelet factor 4/heparin antibodies.

69 Antibodies to the platelet factor 4/heparin complex are a novel, independe

70 We postulated that antibodies to platelet factor 4/heparin complex might contribute to re

71 due primarily to IgG antibodies specific to platelet factor 4/heparin complexes (PF4/Hs) that activa

72 PRT/H Abs showed no cross-reactivity to platelet factor 4/heparin complexes, but were cross-reac

73 heparin therapy caused by antibodies against platelet factor 4/heparin complexes.

74 as diagnosed by the treating physician), and platelet factor 4/heparin IgG antibodies (optical densit

75 All 11 patients tested for the heparin-platelet factor 4 HIT antibody by enzyme-linked immunoso

76 y antibodies against complexes between human platelet factor 4 (hPF4) and heparin.

77 two positively acting sequences in the human platelet factor 4 (hPF4) gene promoter that synergized t

78 ed a panel of HDPs and determined that human platelet factor 4 (hPF4) kills malaria parasites inside

79 Interactions between heparin, human platelet factor 4 (hPF4), antibodies to the hPF4/heparin

80 transcription-induced release of sCD40L and platelet factor 4 in C57BL/6 mice.

81 Roles of IGFBP-1 and platelet factor 4 in HC.HA antiangiogenic action warrant

82 in the absence of clinical disease, such as platelet factor 4 in heparin-induced thrombocytopenia an

83 by determination of beta-thromboglobulin and platelet factor 4 in the supernatants, platelets bound t

84 The presence of platelet factor-4 in the rinse samples was analyzed by W

85 SERPINE1, CCL2) and anti-angiogenic factors (platelet factor 4) in vivo.

86 0, monokine induced by gamma interferon, and platelet factor 4 inhibit epidermal growth factor (EGF)-

87 At this point, 50% of the platelet factor 4 is released, suggesting that half (app

88 Moreover, platelet factor 4 levels and platelet-derived extracellu

89 0, monokine induced by interferon gamma, and platelet factor 4, limit fibroblast responsiveness to gr

90 wth-related protein-alpha (Gro-alpha) and to platelet factor-4-M2 (PF4-M2), an N-terminal chimera of

91 al spatial expression of the chemokine CXCL4/platelet factor-4 marks the progression of fibrosis.

92 PLC-gamma2 and platelet factor 4 mRNA levels were normal.

93 (MIP-1beta), MIP-2, and KC (a member of the platelet factor 4 neutrophil chemoattractant family), as

94 kine C-X-C motif ligand 4 (CXCL4, also named platelet factor 4 or PF4) in the bone marrow, and we fou

95 antimicrobial peptides from human platelets: platelet factor 4 (PF-4), RANTES, connective tissue acti

96 for megakaryocyte specific genes, c-mpl and platelet factor 4 (PF-4).

97 P483H contains the heparin-binding region of platelet factor-4 (PF-4) and a lysine-rich sequence for

98 evidence that changes in platelet-associated platelet factor-4 (PF-4) detect malignant growth across

99 rostate specific membrane antigen (PSMA) and platelet factor-4 (PF-4) in serum were captured on the a

100 , prostate specific membrane antigen (PSMA), platelet factor-4 (PF-4), and interleukin-6 (IL-6) simul

101 , prostate specific membrane antigen (PSMA), platelet factor-4 (PF-4), and interlukin-6 (IL-6).

102 -10, macrophage-derived chemokine [MDC], and platelet factor-4 [PF-4]) to be expressed by CD34(+) cel

103 ing levels of the platelet-derived chemokine platelet factor 4 (PF4) (also known as CXCL4) were eleva

104 APC) improves survival in severe sepsis, and platelet factor 4 (PF4) accelerates APC generation in a

105 that monocytes complexed with surface-bound platelet factor 4 (PF4) activated by HIT antibodies cont

106 evels of the platelet-derived exerkine CXCL4/platelet factor 4 (PF4) ameliorates age-related regenera

107 T) is associated with antibodies that target platelet factor 4 (PF4) and are heparin-independent.

108 irected to large multimolecular complexes of platelet factor 4 (PF4) and heparin (H).

109 mediated by antibodies to complexes between platelet factor 4 (PF4) and heparin or cellular glycosam

110 antibodies that recognize complexes between platelet factor 4 (PF4) and heparin or glycosaminoglycan

111 botic disorder mediated by complexes between platelet factor 4 (PF4) and heparin or other polyanions,

112 aused by antibodies that target complexes of platelet factor 4 (PF4) and heparin.

113 therapy caused by antibodies to complexes of platelet factor 4 (PF4) and heparin.

114 rcoagulable disorder caused by antibodies to platelet factor 4 (PF4) and heparin.

115 s composed of multiple molecules of cationic platelet factor 4 (PF4) and polyanions such as unfractio

116 VITT is caused by anti-platelet factor 4 (PF4) antibodies activating platelets

117 oss-linking of Fc gamma RIIA by anti-heparin/platelet factor 4 (PF4) antibodies is central to the pat

118 cytic niche and associated downregulation of platelet factor 4 (PF4) are pivotal mechanisms driving H

119 Additionally, platelet factor 4 (PF4) binds to bacteria and reduces th

120 arin therapy that is caused by antibodies to platelet factor 4 (PF4) complexed with heparin.

121 Although antibodies to heparin-platelet factor 4 (PF4) complexes are found in essential

122 uires detection of antibodies to the heparin/platelet factor 4 (PF4) complexes via enzyme-linked immu

123 The positively charged chemokine platelet factor 4 (PF4) forms immunogenic complexes with

124 Widely available HIT assays, such as the platelet factor 4 (PF4) heparin enzyme-linked immunosorb

125 activity by ICs containing IgG antibodies to platelet factor 4 (PF4) involved in heparin-induced thro

126 Platelet factor 4 (PF4) is a negative regulator of megak

127 Platelet factor 4 (PF4) is a negative regulator of megak

128 Here we discovered that chemokine platelet factor 4 (PF4) is a negative regulator of Th17

129 Platelet factor 4 (PF4) is an abundant chemokine that is

130 Platelet factor 4 (PF4) is an abundant platelet alpha-gr

131 Platelet factor 4 (PF4) is an abundant platelet alpha-gr

132 iles derived from these models revealed that platelet factor 4 (Pf4) is one of the main upregulated g

133 Platelet factor 4 (PF4) is produced by platelets with ro

134 The platelet-specific chemokine platelet factor 4 (PF4) is released in large amounts at

135 e estrogen receptor under the control of the platelet factor 4 (PF4) megakaryocyte-specific promoter.

136 mmunoglobulin G (IgG) antibodies, which bind platelet factor 4 (PF4) modified by polyanions, such as

137 components forming antigenic complexes with platelet factor 4 (PF4) on platelet surfaces to which an

138 oer et al. demonstrate that youth-associated platelet factor 4 (PF4) partially restores brain functio

139 e recombinase under the control of the mouse platelet factor 4 (Pf4) promoter generated megakaryocyte

140 Platelet factor 4 (PF4) serves as a lineage-specific mar

141 e ultralarge complexes (ULCs) of heparin and platelet factor 4 (PF4) tetramers.

142 xes between unfractionated heparin (UFH) and platelet factor 4 (PF4) that form over a narrow molar ra

143 tight electrostatic binding of the chemokine platelet factor 4 (PF4) to polyanions induces heparin-in

144 The chemokine platelet factor 4 (PF4) undergoes conformational changes

145 Testing for antibodies to platelet factor 4 (PF4) was positive in 22 patients (wit

146 Autoantibodies against platelet factor 4 (PF4) were detected in all patients, a

147 Association of platelet factor 4 (PF4) with heparin is a first step in

148 fic for complexes formed between heparin and platelet factor 4 (PF4), a basic protein found normally

149 Therefore, we investigated the effect of platelet factor 4 (PF4), a cationic protein released in

150 Platelet factor 4 (PF4), a platelet alpha-granule protei

151 We showed that platelet factor 4 (PF4), a platelet-associated chemokine

152 Platelet factor 4 (PF4), a platelet-derived CXC chemokin

153 Platelet factor 4 (PF4), a platelet-specific chemokine r

154 accination vectors versus SARS-CoV-2 bind to platelet factor 4 (PF4), a protein implicated in the pat

155 Platelet factor 4 (PF4), an abundant platelet alpha-gran

156 we used the megakaryocyte-specific promoters platelet factor 4 (PF4), and glycoprotein IIb (GPIIb) as

157 Immune complexes consisting of heparin, platelet factor 4 (PF4), and PF4/heparin-reactive Abs ar

158 Immune complexes consisting of heparin, platelet factor 4 (PF4), and PF4/heparin-reactive antibo

159 brain, alongside platelet concentration and platelet factor 4 (PF4), another neurogenic factor and a

160 sorder caused by immune complexes containing platelet factor 4 (PF4), antibodies to PF4 and heparin o

161 exes of platelet activation: platelet count, platelet factor 4 (PF4), beta-thromboglobulin (beta-TG),

162 genes tested, including GPIbalpha, GPIbbeta, platelet factor 4 (PF4), c-mpl, and p45 NF-E2.

163 Immune complexes consisting of platelet factor 4 (PF4), heparin, and PF4/heparin-reacti

164 by four essential components--heparin (Hep), platelet factor 4 (PF4), IgG antibodies against the Hep-

165 neutrophils and have a structure similar to platelet factor 4 (PF4), in which the first two cysteine

166 ion were observed in response to heparin and platelet factor 4 (PF4), indicating the heterogeneity of

167 pitalised controls and circulating levels of platelet factor 4 (PF4), soluble P-selectin (sP-selectin

168 ces in anticoagulant activity and binding to platelet factor 4 (PF4), which underlies heparin-induced

169 chemokine receptor 1 (Cx3cr1)-expressing and platelet factor 4 (Pf4)-expressing cells.

170 enzyme-linked immunosorbent assay to detect platelet factor 4 (PF4)-heparin antibodies and a modifie

171 We evaluated the presence of antibodies to platelet factor 4 (PF4)-polyanion complexes using a clin

172 Technically simple platelet factor 4 (PF4)-polyanion enzyme-linked immunoso

173 ific for complexes consisting of heparin and platelet factor 4 (PF4).

174 platelet-activating antibodies (Abs) against platelet factor 4 (PF4).

175 telet-activating antibodies directed against platelet factor 4 (PF4).

176 hrombosis, and presence of autoantibodies to platelet factor 4 (PF4).

177 to production of autoantibodies recognizing platelet factor 4 (PF4).

178 dies that recognize an endogenous chemokine, platelet factor 4 (PF4).

179 tiation through the actions of the chemokine platelet factor 4 (PF4).

180 activation, which is further facilitated by platelet factor 4 (PF4).

181 , it forms complexes with positively charged platelet factor 4 (PF4).

182 dies recognize complexes between heparin and platelet factor 4 (PF4).

183 Platelet-activating anti-platelet factor 4 (PF4)/heparin antibodies and anti-PF4

184 performance of 3 immunoassays detecting anti-platelet factor 4 (PF4)/heparin antibodies, derived a di

185 (HIT) is caused by platelet-activating anti-platelet factor 4 (PF4)/heparin antibodies.

186 ients with HIT develop autoantibodies to the platelet factor 4 (PF4)/heparin complex, which is termed

187 Antibodies specific for platelet factor 4 (PF4)/heparin complexes are the hallma

188 othrombotic disorder caused by antibodies to platelet factor 4 (PF4)/heparin complexes.

189 h patients tested strongly positive for anti-platelet factor 4 (PF4)/heparin immunoglobulin (Ig)G in

190 This study demonstrates that a human platelet factor 4 (PF4)/heparin-specific murine monoclon

191 g of the HIT-like monoclonal antibody KKO to platelet factor 4 (PF4)/heparin.

192 Affected patients test strongly positive in platelet factor 4 (PF4)/polyanion enzyme immunoassays (E

193 prochemotactic transcriptome and identified platelet factor 4 (Pf4, also known as CXCL4) as a periva

194 ility that immune complexes formed following platelet factor 4 (PF4/CXCL4) binding to anti-PF4 antibo

195 onstrate that the platelet-derived chemokine platelet factor 4 (PF4/CXCL4) stimulates VSMC injury res

196 g to provide direct evidence that tetrameric platelet factor-4 (PF4) and dimeric interleukin-8 (IL8),

197 Anti-platelet factor-4 (PF4) antibodies were observed in pati

198 ed, with the identification of antibodies to platelet factor-4 (PF4), but without previous heparin ex

199 xes of several human adenoviruses with human platelet factor-4 (PF4), coagulation factors FII (Prothr

200 s overexpression in transgenic mice (via the platelet factor 4 [PF4] promoter) on megakaryocyte devel

201 ting (IL-3) and growth-inhibitory (MIP-1 and platelet factor 4 [PF4]) cytokines, and extracellular ma

202 ration (glycoprotein [GP] Ibalpha, GPIX, and platelet factor 4 [PF4]), whereas GABPalpha-deficient me

203 iomarkers (fractalkine, platelet P-selectin, platelet factor 4 [PF4], and tumor necrosis factor-alpha

204 nfirmed HIT (4Ts score >/=4 points; positive platelet factor 4 [PF4]/heparin immunoassay, positive se

205 Platelet factor 4(PF4), an abundant platelet secretory p

206 he patients had high levels of antibodies to platelet factor 4-polyanion complexes; however, they had

207 r a panel of 8 autoantibodies including anti-platelet factor 4/polyanion (anti-PF4/P), anti-phospholi

208 (tTA), under the control of the MK-specific platelet factor 4 promoter (PF4-tTA-VP16).

209 or transgene expression to platelets using a platelet factor 4 promoter.

210 mbocytopenia antibody" attaches to a heparin-platelet factor 4 protein complex.

211 heparanase but a low affinity for off-target platelet factor-4 protein.

212 osaccharides also exhibit low binding toward platelet factor 4, raising the possibility of preparing

213 myeloperoxidase (MPO)-DNA complexes (NETs), platelet factor 4, RANTES, and selected cytokines.

214 , including neutrophil-activating protein-2, platelet factor-4, RANTES, and macrophage chemotactic pr

215 Serotonin, ADP/ATP, and platelet factor 4 release was profoundly affected in the

216 neration, platelet-derived growth factor and platelet factor 4 release, incorporation of thrombin int

217 tment with rhMIP-1 beta or rhRANTES, but not platelet factor-4, resulted in improved thymic homing of

218 and effectiveness of intravenous recombinant platelet factor 4 (rPF4) as an alternative to protamine

219 well as platelet-derived molecules including platelet factor 4, serotonin, P-selectin, and CD154 (CD4

220 cretable form of the antiangiogenic protein, platelet factor 4 (sPF4).

221 hemokines, monokine induced by IFN-gamma and platelet factor 4 that also generate cAMP, inhibited EGF

222 l expressed and secreted, RANTES) and CXCL4 (platelet factor 4) to the monocyte surface and endotheli

223 GA6, and increased plasma concentrations of platelet factor 4 under basal conditions.

224 otein convertase subtilisin/kexin type 9 and platelet factor-4, whereas they had a minimal inhibitory

225 let and coagulation pathways, including PF4 (platelet factor 4), which may explain the prolonged thro

226 n PEDF and TSP-1 but did contain IGFBP-1 and platelet factor 4 while significantly suppressing neovas

227 CL4L1, is a homologue of CXCL4 chemokine (or platelet factor 4) with potent anti-angiogenic activity